Connect with us

Hi, what are you looking for?

Jewish Business News


Allan Oberman tops Teva’s salary cost list

The former president and CEO Teva Americas Generics earned $7.3 million in 2014.

Allan Oberman


The highest salary cost at Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) in 2014 was for Allan Oberman who stepped down as president and CEO Teva Americas Generics at the end of the year. His salary cost was $7.3 million in 2014, of which $4.5 million was tied to his departure from the company.

However, this is not the end of the road as far as Teva’s payments to Oberman are concerned. As revealed by the F-20 form, “Mr. Oberman is also entitled to receive an amount equal to his annual base salary in consideration for his release and waiver of claims as well as in consideration of, and conditioned upon, his non-compete obligations (which apply for a period of twelve months following his termination date).” That annual base salary is $850, 000.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

Oberman, 57, joined Teva’s senior management in 2000 when Eli Hurvitz was still CEO. Until 2008, he managed Novopharm, which became Teva Canada, and subsequently served as president EMIA (Europe, Middle East, Israel and Africa) and VP international operations division. In 2012, former Teva CEO Jeremy Levin promoted him to CEO Americas Generics.

Current CEO Erez Vigodman has implemented an organizational restructuring, which including setting up a Global Generics Medicine Group headed by Sigurdur Olafsson who came into the company and is also responsible for Generics America, which had been under Oberman’s management.

Teva’s second highest salary cost in 2014 was president of Global R&D and Chief Scientific Officer Dr. Michael Hayden, who weighed in with $5.2 million, while president and CEO Erez Vigodman only had the third highest salary cost at $4.5 million.

Published by Globes [online], Israel business news –



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Copyright © 2021 Jewish Business News